| July 14, 2003
Laura Demopoulos, MD, Joins UPHS
As Director of the Women's Heart Program
(Philadelphia, PA) -- Laura A.
Demopoulos, MD, has been appointed Clinical Associate
Professor of Medicine in the Cardiovascular Medicine
Division of the University of Pennsylvania School
of Medicine, and Director of the Women's Heart Program
for the University of Pennsylvania Health System.
She will practice at PENN Medicine at Radnor, effective
"Dr. Demopoulos brings to Penn a practiced hand in
patient care as well as extensive experience in clinical
trials and patient-oriented research, and we are delighted
she has agreed to serve as Director of our expanding
Women's Heart Program in the Division," said Michael
S. Parmacek, MD, Chief of the Cardiovascular Division
in Penn's School of Medicine.
Demopoulos, a board-certified physician in internal
medicine and cardiovascular diseases, comes to Penn
from Merck and Co., Inc, where she was Executive Director
of the pharmaceutical company's Cardiovascular Research
Department. She has also served for the past six years
as an attending physician in the Cardiology Fellows
Clinic at the Hospital of the University of Pennsylvania
(HUP), and prior to that served as an attending physician
at Albert Einstein Medical School in New York.
She earned her medical degree from New York University
and completed her internship, residency, Chief Residency
and fellowship at New York University Medical Center.
She did research in heart failure at Albert Einstein
College of Medicine in New York before joining Merck.
Demopoulos has held teaching positions at the Massachusetts
Institute of Technology and at New York University Medical
Center and Albert Einstein. She has conducted extensive
research in the field of cardiology and has contributed
to more than 60 published research articles.
At PENN Medicine at Radnor, Demopoulos is building
a multi-disciplinary team that offers medical care designed
to address the specific needs of women in treating and
preventing heart disease.
"Women have a different onset of symptoms and different
risk factors than men, and so we are creating a program
designed especially for women's cardiovascular health,"
All heart patients have access to electrophysiologists;
preventive and interventional cardiologists; and heart-failure
and transplant specialists at PENN Medicine at Radnor.
The comfortable, suburban facility also offers a complete
range of cardiac diagnostic services, including electrocardiograms;
exercise stress testing; exercise stress cardiography;
echocardiography; nuclear imaging; treatment and consultation
related to pacemakers and implantable defibrillators;
and Holter and cardiac event monitoring.
Editor's note: You may also find this news release
online at www.uphs.upenn.edu
PENN Medicine is a $2.2 billion enterprise dedicated
to the related missions of medical education, biomedical
research, and quality patient care. PENN Medicine consists
of the University of Pennsylvania School of Medicine
(founded in 1765 as the nation's first medical school)
and the University of Pennsylvania Health System (created
in 1993 as the nation's first integrated academic health
system). Penn's School of Medicine is ranked #2 in the
nation for receipt of NIH research funds; and ranked
#4 in the nation in U.S. News & World Report's most
recent ranking of top research-oriented medical schools.
Supporting 1400 fulltime faculty and 700 students, Penn's
School of Medicine is recognized worldwide for its superior
education and training of the next generation of physician/scientists
and leaders of academic medicine. Penn's Health System
consists of four hospitals (including its flagship Hospital
of the University of Pennsylvania, consistently rated
one of the nation's "Honor Roll" hospitals by U.S. News
& World Report); a faculty practice plan, a primary-care
provider network, three multispecialty satellite facilities,
and home healthcare and hospice.